Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK T474I BTK C481S |
| Therapy | Pirtobrutinib |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK T474I BTK C481S | chronic lymphocytic leukemia | predicted - resistant | Pirtobrutinib | Case Reports/Case Series | Actionable | In a clinical case study, Jaypirca (pirtobrutinib) treatment resulted in a continued decrease of cancer cell fraction (CCF) of a clone of cells harboring BTK C481S but persistent increase of a clone harboring BTK T474I in a patient with chronic lymphocytic leukemia, as well as low-level CCF increase of BTK T474L, and BTK M477I (PMID: 36287227). | 36287227 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36287227) | Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. | Full reference... |